NASDAQ 100 % ()
FTSE 100 % ()
DOLLAR INDEX % ()
BTC/USD % ()
EUR/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()
CRUDE OIL % ()

INO

Inovio Pharmaceuticals Inc. Nasdaq Global Select
$10.35
Open: $9.03 High: $10.325 Low: $8.925 Close: $10.31
Range: 2021-01-25 - 2021-01-26
Volume: 25,039,908
Market: Open
Powered by Finage Stock APIDelayed data
INO
Inovio Pharmaceuticals Inc. 660 West Germantown Pike Plymouth Meeting PA, 19462 http://www.inovio.com
Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.
  • CEO: J. Joseph Kim
  • Employees: 278
  • Sector: Healthcare
  • Industry: Biotechnology
INO News
Latest news about the INO
  • INOVIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

    INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the closing of its previously announced underwritten public offering of 20,355,000 shares of its common stock, which includes 2,655,000 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $8.50 per share. The gross proceeds to INOVIO from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $173 million.

    View More →
  • Should Inovio Be On Your Buy List As It Tackles A Coronavirus Vaccine?

    Inovio has thrown its hat into the coronavirus vaccine ring with big biopharma names like Moderna, Johnson & Johnson and Pfizer. But INO stock is volatile on its vaccine news.

    View More →
  • What Is The Ownership Structure Like For Inovio Pharmaceuticals, Inc. (NASDAQ:INO)?

    If you want to know who really controls Inovio Pharmaceuticals, Inc. ( NASDAQ:INO ), then you'll have to look at the...

    View More →
  • Inovio Falls After $150 Million Share Offering Unveiled

    Inovio said in December that its covid vaccine candidate was in Phase 2 clinical trials. It's now raising new capital to help finance its clinical pipeline.

    View More →
  • Inovio's stock falls after it announces public offering

    Shares of Inovio Pharmaceuticals Inc. were down 5.1% in premarket trading on Thursday, the day after the company announced a public offering of 17,700,000 shares at $8.50 per share. The stock closed Wednesday at $9.72. Inovio said it will use the proceeds to support its clinical pipeline, which includes ongoing development of its COVID-19 vaccine candidate, which is currently being tested in a mid-stage clinical trial, and general corporate expenses. The offering is expected to close Jan. 25. Inovio's stock has rallied 173.0% over the past year, while the S&P 500 is up 14.5%

    View More →
  • The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20) * 10X Genomics Inc (NASDAQ: TXG) * ABIOMED, Inc. (NASDAQ: ABMD) * Aclaris Therapeutics Inc (NASDAQ: ACRS) * Adamis Pharmaceuticals Corp(NASDAQ: ADMP) (announced IND submission of Tempol for COVID-19 treatment) * Akari Therapeutics PLC (NASDAQ: AKTX) * Aligos Therapeutics Inc (NASDAQ: ALGS) * Alimera Sciences Inc (NASDAQ: ALIM) * Atea Pharmaceuticals Inc (NASDAQ: AVIR) * Beigene Ltd (NASDAQ: BGNE) * Bicycle Therapeutics PLC (NASDAQ: BCYC) * BIO-TECHNE Corp (NASDAQ: TECH) * BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) * Biodesix Inc (NASDAQ: BDSX) * BioVie Inc (NASDAQ: BIVI) * Caladrius Biosciences Inc (NASDAQ: CLBS) * Cara Therapeutics Inc (NASDAQ: CARA) * CareDx Inc (NASDAQ: CDNA) * Castle Biosciences Inc (NASDAQ: CSTL) * Celcuity Inc (NASDAQ: CELC) * Cellectis SA (NASDAQ: CLLS) * Celsius Holdings, Inc. (NASDAQ: CELH) * Dare Bioscience Inc (NASDAQ: DARE) * DermTech Inc (NASDAQ: DMTK) * Dyne Therapeutics Inc (NASDAQ: DYN) * Edap Tms SA (NASDAQ: EDAP) (reacted to fourth-quarter results) * Eli Lilly And Co (NYSE: LLY) * ENDRA Life Sciences Inc (NASDAQ: NDRA) * ESSA Pharma Inc (NASDAQ: EPIX) * Evelo Biosciences Inc (NASDAQ: EVLO) (announced positive Phase 1b data for drug to treat atopic dermatitis) * EXACT Sciences Corporation (NASDAQ: EXAS) * Fulgent Genetics Inc (NASDAQ: FLGT) * Genetron Holdings Ltd - ADR (NASDAQ: GTH) * Gritstone Oncology Inc (NASDAQ: GRTS) (announced a nonexclusive license to Genevant's LNP technology to develop vaccines against SARS-CoV-2) * Guardant Health Inc (NASDAQ: GH) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Idera Pharmaceuticals Inc (NASDAQ: IDRA) * Ideaya Biosciences Inc (NASDAQ: IDYA) * ImmuCell Corporation (NASDAQ: ICCC) * Inari Medical Inc (NASDAQ: NARI) * Infinity Pharmaceuticals Inc. (NASDAQ: INFI) * Inspire Medical Systems Inc (NYSE: INSP) * Insulet Corporation (NASDAQ: PODD) * Integra Lifesciences Holdings Corp (NASDAQ: IART) * Inventiva ADR Representing Ord Shs (NASDAQ: IVA) * iTeos Therapeutics Inc (NASDAQ: ITOS) * Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) * Johnson & Johnson (NYSE: JNJ) * Jounce Therapeutics Inc (NASDAQ: JNCE) * Krystal Biotech Inc (NASDAQ: KRYS) * LeMaitre Vascular Inc (NASDAQ: LMAT) * Ligand Pharmaceuticals Inc. (NASDAQ: LGND) * Maravai Lifesciences Holdings Inc (NASDAQ: MRVI) * Merus NV (NASDAQ: MRUS) * Mustang Bio Inc (NASDAQ: MBIO) * Natera Inc (NASDAQ: NTRA) * Neuronetics Inc (NASDAQ: STIM) * Obalon Therapeutics Inc (NASDAQ: OBLN) (announced a deal to merge with ReShape Lifesciences) * Organogenesis Holdings Inc (NASDAQ: ORGO) * Orphazyme A S ADR (NASDAQ: ORPH) * Pacific Biosciences of California Inc (NASDAQ: PACB) * PRA Health Sciences Inc (NASDAQ: PRAH) * Precision BioSciences Inc (NASDAQ: DTIL) * Relay Therapeutics Inc (NASDAQ: RLAY) * Repligen Corporation (NASDAQ: RGEN) * Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) * Profound Medical Corp (NASDAQ: PROF) * Stoke Therapeutics Inc (NASDAQ: STOK) * Supernus Pharmaceuticals Inc (NASDAQ: SUPN) * Surface Oncology Inc (NASDAQ: SURF) * Syneos Health Inc (NASDAQ: SYNH) * Titan Medical Inc. (NASDAQ: TMDI) * Twist Bioscience Corp (NASDAQ: TWST) * Vericel Corp (NASDAQ: VCEL) * Xencor Inc (NASDAQ: XNCR) * Zai Lab Ltd - ADR (NASDAQ: ZLAB)Down In The Dumps None of the biotech/medical device/diagnostic stocks hit 52-week highs in the session.Stocks In Focus Bristol-Myers Squibb's Regulatory Application For Esbriet Label Expansion Accepted For Priority Review Bristol-Myers Squibb Co (NYSE: BMY) said the FDA has accepted its supplemental New Drug Application and granted priority review for Esbriet for the treatment of unclassifiable interstitial lung disease. The FDA is expected to make a decision on approval by May 2021.Addex Says Licensee J&J's Janssen Unit Approved To Start Phase 2a Epilepsy Drug Study Addex Therapeutics ADR (NASDAQ: ADXN) said its partner Johnson & Johnson's Janssen Pharmaceuticals has received FDA investigational new drug approval to begin a Phase 2a proof-of-concept study with the selective metabotropic glutamate type 2 receptor positive allosteric modulator JNJ-40411813 in patients with epilepsy. The first patient is expected to be treated during the second quarter of 2021.Janssen licensed the pipeline asset from Addex.Addex shares were soaring 67.87% to $17.10 premarket Thursday.Boston Scientific To Buy Cardiac Health Solutions Provider Preventice Boston Scientific Corporation (NASDAQ: BSX) said it has entered into a definitive agreement to acquire Preventice Solutions, Inc., a privately held company offering a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors -- including short and long-term Holter monitors -- to cardiac event monitors and mobile cardiac telemetry.The transaction consists of an upfront cash payment of $925 million and up to an additional $300 million in potential commercial milestone payments.Boston now holds an equity stake of approximately 22%, which is expected to result in a net payment of approximately $720 million upon closing and a milestone payment of up to approximately $230 million.INmune Bio Reports Positive Early Stage Data For Alzheimer's Drug INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company, said results from a Phase 1b study demonstrate that its Alzheimer's disease candidate XPro1595 led to decreasing neuroinflammation, with significant improvements in biomarkers of neurodegeneration and synaptic function.The stock was rallying 41.88% to $35.64 premarket Thursday.Related Link: The Week Ahead In Biotech: FDA To Issue Decisions On Merck And Aurinia Drug Applications Lineage Cell CFO to Depart Lineage Cell Therapeutics Inc (NYSE: LCTX) said Brandi Roberts, its chief financial officer, provided notice of her resignation Jan. 15 in order to accept a leadership position at another company. Brian Culley, Lineage's CEO, will serve as interim chief financial officer until a CFO has been appointed, the company said.The stock was up 9.67% at $3.29 premarket. Dynavax Appoints Ironwood Pharma Executive As CFO Dynavax Technologies Corporation(NASDAQ: DVAX) announced the appointment of Kelly MacDonald as SVP and chief financial officer effective March 1. MacDonald will replace Michael Ostrach, who is retiring following a 14-year stint at the company.MacDonald last served as chief accounting officer and VP of finance at Ironwood Pharmaceuticals, Inc.(NASDAQ: IRWD).Ora Sure's Saliva Collection Device Included In FDA Authorized Exome Sequencig-Based Platform OraSure Technologies, Inc. (NASDAQ: OSUR) said its Oragene Dx (OGD-610) saliva collection device was included as a component in the De Novo authorization granted by the FDA to Helix for their Helix Laboratory Platform, a whole exome sequencing platform. This is the first exome sequencing-based platform authorized by the FDA. Oragene Dx is a product of OraSure's DNA Genotek subsidiary.The stock was up 8.18% to $14.42 in premarket trading Thursday.Offerings Inovio Pharmaceuticals Inc (NASDAQ: INO), which is developing a DNA vaccine for the coronavirus vaccine, priced its underwritten public offering of 17.7 million shares of its common stock at $8.5 per share, for raising gross proceeds of $150.5 million. All of the shares are being sold by Inovio. The company said it intends to use the net proceeds from this offering for the development of its clinical pipeline, including clinical development expenses relating to INO-4800 and R&D expenses, and for general corporate purposes, including working capital and general and administrative expenses.The stock shed 7.3% premarket to $9.01.Dyne Therapeutics priced its underwritten public offering of 6 million shares of its common stock at a public offering price of $28 per share, for raising gross proceeds of $168 million. All of the shares are being offered by Dyne.OncoSec Medical Inc (NASDAQ: ONCS) said it intends to offer shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by the company.The stock was down 4.51% premarket at $5.50. OncoCyte Corp (NYSE: OCX) announced that it has entered into definitive agreements with its two largest institutional investors -- Pura Vida and Broadwood Partners -- to purchase approximately $25 million of its common shares in a registered offering priced at $3.424 per share.The stock jumped 10.68% premarket to $4.56.InVitae Corp (NYSE: NVTA) said it has commenced an underwritten public offering of $400 million of shares of its common stock. All of the shares are being offered by the company.The stock was down 2.86% premarket at $55.30. Related Link: Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates See more from Benzinga * Click here for options trades from Benzinga * The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study * The Week Ahead In Biotech: FDA To Issue Decisions On Merck And Aurinia Drug Applications(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Inovio Sinks 7% After Pricing Of $150.5M Share Offering; Street Says Hold

    Shares of Inovio Pharmaceuticals dropped about 7% in Thursday’s pre-market trading after the biotech company priced its $150.5 million share offering. Inovio (INO) is offering to sell 17,700,000 shares of its common stock at a price of $8.50 per piece, reflecting a 14% discount to the closing price on Jan. 20. Furthermore, Inovio has granted the underwriters of the offering a 30-day option to buy up to an additional 2,655,000 shares of common stock. The share sale is expected to close by January 25, pending customary closing conditions. BofA Securities, Jefferies and Cantor are acting as joint book-running managers for the offering. Inovio describes itself as the only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. The biotech company has a number of programs in development targeting HPV-related cancers, recurrent respiratory papillomatosis, and prostate cancer, among others. Additionally, Inovio is currently conducting clinical trials for INO-4800, its COVID-19 vaccine candidate, which targets the major antigen spike protein of the SARS-CoV-2 virus. “Inovio intends to use the net proceeds from this offering for the development of its clinical pipeline, including clinical development expenses relating to INO-4800 and research and development expenses, and for general corporate purposes, including working capital and general and administrative expenses,” the company stated. As Inovio shares have already surged a stellar 196% over the past year, analysts are sidelined on the stock with a Hold consensus. Looking ahead, the average analyst price target of $13 indicates additional upside potential of 34% over the coming 12 months. Earlier this month, Benchmark analyst Aydin Huseynov slashed the stock's price target to $15 from $25 in view of the operational challenges of INO-4800 trials and manufacturing amid a "shrinking and competitive market" for COVID-19 vaccines. However, Huseynov stuck to his Buy rating, citing "potentially significant upside" for the stock if Inovio inks pre-sales deals of INO-4800 with multiple foreign governments. (See Inovio stock analysis on TipRanks). Furthermore, the analyst believes that the company would need to enter into a partnership with a “strong and reputable” biopharma partner to help with the operational capacity and speed to manufacture several hundred million vaccine doses in 2021 and beyond. Related News: Aclaris Explodes 220% On ‘Positive Data’ From Rheumatoid Arthritis Trial Netflix’s Subscriber Growth Fuel 4Q Sales Boom; Shares Pop 12% JPMorgan’s 4Q Profit Beats Analysts’ Estimates More recent articles from Smarter Analyst: Boeing Wins $2.1B US Air Force Contract For KC-46 Tankers Tesla’s California Registrations Surge 63% in 4Q - Report P&G Fiscal 2Q Results Beat Estimates, Raises Outlook Kinder Morgan Gains On Quarterly Profit Beat; Street Says Hold

    View More →
  • INOVIO Announces Pricing of Public Offering of Common Stock

    INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the pricing of an underwritten public offering of 17,700,000 shares of its common stock at a public offering price of $8.50 per share. In addition, INOVIO has granted the underwriters a 30-day option to purchase up to an additional 2,655,000 shares of common stock at the public offering price, less underwriting discounts and commissions. Gross proceeds to INOVIO from the offering are expected to be approximately $150.5 million, before deducting underwriting discounts and commissions and estimated offering expenses, but excluding any exercise of the underwriters' option. All of the shares are being sold by INOVIO.

    View More →
  • INOVIO Announces Proposed Public Offering of Common Stock

    INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock. All of the shares are being offered by INOVIO. In addition, INOVIO intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering.

    View More →
  • Inovio’s (INO) INO-4800 can be a Valuable Vaccine Arsenal Upon FDA Approval

    Wasatch Advisors, an employee-owned investment manager, published its ‘Wasatch Micro Cap Value Fund’ third-quarter 2020 Investor Letter – a copy of which can be downloaded here. A return of 11.62% was recorded by the fund for the Q3 of 2020, above its Russel Microcap benchmark that returned 3.69%. You can view the fund’s top 10 […]

    View More →
  • Inovio: Advaccine Deal Is a Positive but Not a Game Changer, Analyst Says

    Inovio Pharmaceuticals’ (INO) 2020 was a tale of two contrasting halves. Shares skyrocketed during the first 6 months as the small vaccine maker entered the Covid-19 vaccine race and caught a ride on investors’ appetite for coronavirus-focused stocks. However, the year’s second half was marred by disappointment as the company failed to keep up with the pace setters. No doubt, in 2021, investors would like a repeat of last year’s initial surge. Meanwhile, on Monday, Inovio announced a collaboration and licensing deal for its COVID-19 DNA vaccine candidate INO-4800.The company has partnered with China-based Advaccine Biopharmaceuticals who will own the exclusive rights to develop, produce and bring to market INO-4800 in Greater China, including Hong Kong, Macao and Taiwan.In return, Advaccine’s plasmid manufacturing process will be licensed to Inovio for the development of INO-4800. Advaccine will pay Inovio an upfront fee of $3 million and milestone payments totaling $108 million. Inovio will also be eligible to collect royalties equal to a high single-digit percentage of yearly net sales in each region across Greater China.H.C Wainwright analyst Ram Selvaraju believes the agreement “enables Inovio to monetize the global market potential of INO-4800 and adds an Asian manufacturing partner into its global manufacturing consortium.”INO-4800 is currently in a Phase 2 trial in China, which is “progressing well, with all 640 subjects dosed for the first vaccination.” The trial has a similar design to the Phase 2 study currently taking place in the U.S.The progress, however, is not enough of a game changer for Selvaraju to readjust his Inovio model.The analyst cites “the uncertainty of the commercial outlook for Inovio's vaccine in the context of the current competitive landscape and the trajectory of the global pandemic,” as the reasons why he remains Neutral (i.e. Hold) for now. The analyst has no specific price target in mind. (To watch Selvaraju’s track record, click here)On the rating front, Selvaraju’s colleagues agree. The consensus among analysts is a Hold, based on 1 Buy and Sell, each, and 5 Holds. However, the average price target is an optimistic one, and at $12.6 could provide investors with returns of 36% over the next 12 months. (See INO stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

    View More →
  • INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18

    INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and HPV-associated diseases, today announced positive efficacy results for an open-label Phase 2 trial of VGX-3100 to treat HPV-16 and HPV-18-associated vulvar dysplasia. A 25% or more reduction in HPV-16/18-associated vulvar HSIL (high-grade squamous intraepithelial lesion) was observed for 63% of trial participants (12 of 19) treated with VGX-3100 at six months post-treatment. Three out of the 20 participants with histology data (15%) resolved their vulvar HSIL and had no HPV-16/18 virus detectable in the healed area. By comparison, the spontaneous resolution of vulvar HSIL caused by HPV-16/18 is estimated to be only 2%. The trial also showed VGX-3100 to be safe and well-tolerated. Based upon these results INOVIO is planning to pursue Phase 3 development.

    View More →
  • Inovio Strikes $100M Coronavirus Vaccine Licensing Deal With China's Advaccine

    Shares of Inovio Pharmaceuticals Inc (NASDAQ: INO), which is developing a DNA vaccine against the novel coronavirus, were advancing Monday.What Happened: Plymouth Meeting, Pennsylvania-based Inovio announced a collaboration and licensing agreement with China-based biotech Advaccine Biopharma to market its investigational vaccine INO-4800 in the Greater China region.The agreement provides Advaccine with the exclusive rights to develop, manufacture and commercialize INO-4800 within Greater China, which includes mainland China, Hong Kong, Macau and Taiwan.Advaccine will license its plasmid manufacturing process to Inovio for INO-4800 and other pipeline products. sublicense the rights to its manufacturing partners. Advaccine will also provide its clinical data to Inovio to be used in the latter's global regulatory filings for INO-4800.Related Link: Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates The Terms Of The Deal: Inovio stands to receive an upfront payment of $3 million as well as $108 million in milestone payments, contingent upon achievement of specified development and sales-based milestones for INO-4800 in Greater China.Inovio is also entitled to receive royalties equivalent to a high single-digit percentage of annual sales of INO-4800 in the region.Why It's Important: Following a clinical hold imposed by the FDA in late September, Inovio received the green light to commence the Phase 2 portion of the U.S. Phase 2/3 trial of INO-4800 in mid-November.Inovio has also commenced a Phase 2 study of the vaccine candidate in China in collaboration with Advaccine."INOVIO's partnership with Advaccine enables us to leverage their deep expertise, capabilities and network across the region - making it possible to rapidly produce and if and when approved, distribute our vaccine candidate to more people across Greater China," CEO Joseph Kim said in a statement. INO Price Action: In premarket trading Monday, Inovio shares were rising 1.69% to $9.Related Link: SVB Leerink Bullish On Silverback Therapeutics, Sees Diverse Pipeline See more from Benzinga * Click here for options trades from Benzinga * Nio Launches 'NIO Certified' Used Car Service in China Amid Competitive Pressure From Tesla * Nio's Record Run Continues As Deliveries Spike 121% In December; EV Maker Confirms Sedan Launch On 'Nio Day'(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Inovio to partner with Chinese biotech on COVID-19 vaccine candidate in Greater China

    Shares of Inovio Pharmaceuticals Inc. were up 4.5% in premarket trading on Monday after the company announced a licensing deal with Advaccine Biopharmaceuticals Suzhou Co. Ltd. for its COVID-19 vaccine candidate. As part of the agreement, the privately held Chinese biotech gains exclusive right to develop, manufacture, and commercialize the still-investigational vaccine in China, Hong Kong, Macao, and Taiwan. Advaccine will make an upfront payment of $3 million to Inovio, with additional possible milestone payments up to $108 million. Inovio may receive royalties based on annual net sales in the region if the vaccine is authorized or approved, though the company's COVID-19 vaccine candidate has not been authorized or approved in any countries. A Phase 2 clinical trial in China is currently underway. Inovio's stock has soared 196.9% over the last year, while the S&P 500 is up 16.2%.

    View More →
  • INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China

    INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co., Ltd. ("Advaccine"), an emerging biotech company with next-generation technology in vaccines, both preventive and therapeutic, today announced that they have entered into a collaboration and license agreement for COVID-19 DNA vaccine candidate INO-4800.

    View More →
  • Could Inovio Pharmaceuticals Be a Millionaire-Maker Stock?

    This coronavirus vaccine drugmaker has already made many of its early investors rich, but its valuation is still dirt cheap.

    View More →
  • Why Inovio Stock Sank Today

    Analysts have very different takes on the early-stage results for the company's COVID-19 vaccine candidate.

    View More →
  • Company News for Dec 28, 2020

    Companies In The News Are: BUD, APO, INO, GOOGL, INTC, CLDR

    View More →
  • Is Inovio Pharmaceuticals (INO) a Smart Long-term Buy?

    Wasatch Micro Cap Fund recently released its Q3 2020 Investor Letter, a copy of which you can download here. The fund posted a return of 12.2% for the quarter, outperforming its benchmark, the Russell Microcap Index which returned 3.69% in the same quarter. You should check out Wasatch’s top 5 stock picks for investors to […]

    View More →
  • Inovio Shares Rise On Positive Data For Coronavirus Vaccine Candidate That's Stable At Room Temps

    Inovio Pharmaceuticals Inc (NASDAQ: INO) shares were trading higher Thursday after the company released positive Phase 1 data on to its COVID-19 DNA vaccine candidate.What Happened: On Wednesday, Inovio published a paper including Phase 1 data on INO-4800, which was found to have been immunogenic in all test subjects.In addition, Phase 1 testing generated no serious adverse safety events and only six Grade I adverse events, which were mostly minor injection site reactions.Related Link: Why A COVID-19 Vaccine Makes General Electric's Stock 'More Investable'Why It's Important: Inovio's INO-4800 coronavirus vaccine candidate didn't come close to winning the race to market given that vaccines from Pfizer Inc. (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) are already authorized by the FDA.Yet Moderna's vaccine must be stored and transported at temperatures of negative 20 Celsius, and Pfizer's vaccine must be stored and transported at temperatures of negative 70 Celsius, colder than winter temperatures in Antarctica.INO-4800, on the other hand, is stable at room temperature for more than one year. It also doesn't need to be frozen during transporter storage, potentially making it faster and more cost-effective to distribute.Inovio shares are up 205% year-to-date but have declined 53.3% in the last six months as competing vaccine candidates seemingly pulled ahead in the race to combat the pandemic.Benzinga's Take: Assuming it is as effective and safe as competing vaccines, Inovio's candidate could ultimately end up being the standard-bearer for COVID-19 and future coronavirus vaccine variants.Analysts have estimated the global COVID-19 vaccine market could be worth $10 billion annually, so it's understandable why Inovio investors are excited given the company's $1.7-billion market cap.See more from Benzinga * Click here for options trades from Benzinga * 10 Tips To Bring Positivity Into Your Trading Day (And Life) * Nikola Option Traders React To Canceled Republic Services Deal(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →